Patents Assigned to ICON BIOSCIENCE, INC.
  • Patent number: 10159683
    Abstract: The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: December 25, 2018
    Assignee: ICON BIOSCIENCE, INC.
    Inventors: Vernon G. Wong, William S. White, Mae W. Hu, Glenn T. Huang, Faina Karasina
  • Patent number: 10028965
    Abstract: The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: July 24, 2018
    Assignee: ICON BIOSCIENCE, INC.
    Inventors: Vernon G. Wong, William S. White, Mae W. Hu, Glenn T. Huang, Faina Karasina
  • Patent number: 10022502
    Abstract: Devices that guide the accurate loading and dispensing of predetermined doses of fluid from injection syringes are disclosed.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: July 17, 2018
    Assignee: ICON BIOSCIENCE, INC.
    Inventors: Vernon G. Wong, Tan Pham, William S. White, Glenn T. Huang, Mae W. Hu
  • Patent number: 9814773
    Abstract: The present invention provides for injectable pharmaceutical sustained release formulations for delivery of active agents, particularly therapeutic proteins, to the eye. The formulations are biocompatible, biodegradable sustained release formulations comprising low-solubility liquid excipients and relatively small amounts (less than about 10%) of biocompatible, biodegradable polymer such as PLA or PLGA polymers. A unit dose of 5 ?L to 100 ?L of the formulation provides for sustained release of the agent for at least 14 days.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: November 14, 2017
    Assignees: Ramscor, Inc., Icon Bioscience, Inc.
    Inventors: Vernon G. Wong, Louis L. Wood, Carol Wood, Glenn T. Huang
  • Patent number: 9636347
    Abstract: The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: May 2, 2017
    Assignee: Icon Bioscience, Inc.
    Inventors: Vernon G. Wong, Mae W. Hu, Glenn T. Huang
  • Patent number: 9283231
    Abstract: The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: March 15, 2016
    Assignee: Icon Bioscience, Inc.
    Inventors: Vernon G. Wong, Mae W. Hu, Glenn T. Huang
  • Publication number: 20140180245
    Abstract: Devices that guide the accurate loading and dispensing of predetermined doses of fluid from injection syringes are disclosed.
    Type: Application
    Filed: April 25, 2012
    Publication date: June 26, 2014
    Applicant: ICON BIOSCIENCE, INC.
    Inventors: Vernon G. Wong, Tan Pham, William S. White, Glenn T. Huang, Mae W. Hu
  • Publication number: 20140140992
    Abstract: The present invention provides for injectable pharmaceutical sustained release formulations for delivery of active agents, particularly therapeutic proteins, to the eye. The formulations are biocompatible, biodegradable sustained release formulations comprising low-solubility liquid excipients and relatively small amounts (less than about 10%) of biocompatible, biodegradable polymer such as PLA or PLGA polymers. A unit dose of 5 ?L to 100 ?L of the formulation provides for sustained release of the agent for at least 14 days.
    Type: Application
    Filed: June 11, 2012
    Publication date: May 22, 2014
    Applicants: ICON BIOSCIENCE, INC., RAMSCOR, INC.
    Inventors: Vernon G. Wong, Louis L. Wood, Glenn T. Huang